



**Gervasio A. Lamas, MD**  
*Principal Investigator*  
[tactnih@aol.com](mailto:tactnih@aol.com)

Dear Cardiologist,

Your patient has expressed interest in participating in the Trial to Assess Chelation Therapy (TACT), a double-blind, placebo-controlled trial sponsored by the National Institutes of Health. TACT will randomize 2,372 patients in an effort to find a definitive answer on the efficacy of EDTA chelation therapy for coronary heart disease. Patient eligibility is broad—the trial is looking for **post MI, non-smoking patients, 50 or older with a creatinine level less than 2.0mg**. TACT will be a landmark trial that not only looks at EDTA chelation, but also evaluates whether high dose antioxidant vitamin and mineral supplements have any clinical benefits in treating coronary heart disease. The 2x2 factorial design randomizes patients into two arms to independently test the effects of a standard EDTA chelation solution versus placebo solution, and the effects of high-dose supplementation versus placebo.

As a trial participant, your patient will be closely monitored during every infusion. In addition, as part of our protocol, patient labs are collected and monitored to ensure each participant's safety. These labs are provided at no cost to trial participants. As part of our safety measures, we notify patients of any lab abnormalities and contact the patient's PCP when contact information is available to us. Your referral will help us determine whether EDTA chelation and/or high dose vitamins and minerals are beneficial, harmful or neutral for patients with coronary disease.

Thank you for your time and I hope that you will allow your patient to participate in TACT. If you would like additional information about the trial, please contact me at TACT's Clinical Coordinating Center at (305) 674-2162 or at [tactnih@aol.com](mailto:tactnih@aol.com).

Sincerely,

A handwritten signature in black ink, appearing to read "G. Lamas".

Gervasio Lamas, MD  
Principal Investigator